v3.26.1
Revenue (Details)
$ in Thousands, ¥ in Billions
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Mar. 31, 2025
JPY (¥)
Jan. 31, 2024
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Revenue recognized     $ 1,662 $ 2,666 $ 3,403 $ 20,055      
Deferred revenue, current     6,669   6,669   $ 1,458    
Deferred revenue, non-current             2,611    
ACELYRIN                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Development, regulatory and commercial milestone payments                 $ 157,500
License                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Revenue recognized           17,389      
Collaboration                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Revenue recognized     1,662 2,666 3,403 2,666      
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Upfront, non-refundable payment   $ 20,000              
Global development cost reimbursement   20,000              
Maximum achievement of regulatory milestones   36,000              
Maximum achievement of commercial milestones | ¥               ¥ 15.5  
Amount allocated to license obligation   17,400              
Amount allocated to Development Services Obligation   20,800              
Amount allocated to Material Right Obligation   3,300              
Revenue recognized     1,700 0 3,400 0      
Collaboration revenue receivable     0   0        
Deferred revenue, current     6,700   6,700   1,500    
Deferred revenue, non-current     0   0   2,600    
Estimated amount of transaction price unsatisfied     14,200   14,200        
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Less than                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Collaboration revenue receivable             $ 100    
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | License obligation | License                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Revenue recognized     0 0 0 17,400      
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Development services obligation and manufacturing services obligation | Collaboration                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Revenue recognized     1,700 $ 2,700 3,400 $ 2,700      
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Development services obligation                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Estimated amount of transaction price unsatisfied     10,900   10,900        
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Material right obligation                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Estimated amount of transaction price unsatisfied     $ 3,300   $ 3,300        
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Global development cost reimbursement in the dermatology field through the end of 2026                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Global development cost reimbursement   20,000              
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Estimated global development cost reimbursement in the dermatology field after 2026                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Global development cost reimbursement   $ 1,500              
Climb Bio                  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                  
Development milestone payment in dispute $ 3,000                
Development milestone payment to seek $ 3,000